• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Therapy of hepatitis C: Interferon alfa-2a trials

  1. W M Lee

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510260716

Issue

Hepatology

Hepatology

Supplement: Management of Hepatitis C: 2002

Volume 26, Issue Supplement 3, pages 89S–95S, December 1997

Additional Information

How to Cite

Lee, W. M. (1997), Therapy of hepatitis C: Interferon alfa-2a trials. Hepatology, 26: 89S–95S. doi: 10.1002/hep.510260716

Author Information

  1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235-9151, USA

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (183K)

References

  • 1
    Ryff J.-C. Usefulness of interferon for treatment of hepatitis C. J Hepatol 1995; 22 (suppl 1): 101–109.
  • 2
    Emanuel S, Pestka S. Human interferon-alphaA, -alpha2, and -alpha2 (Arg) genes in genomic DNA. J Biol Chem 1993; 268: 12565–12569.
  • 3
    Schmid-Hoffman E, Wolfe L, Smith P, Waldy C, Ryff J.-C. Final study report: results from serial HCV RNA determinations using a quantitative PCR method. Roche Research Report N. B-154.142, 1995.
  • 4
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435.
    Direct Link:
  • 5
    Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, Frezza M, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993; 17 (suppl 3): S123–126.
  • 6
    Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700–706.
  • 7
    Rumi M, Del Ninno E, Parravicini MLK, Romeo R, Soffredini R, Donate MF, Wifber J, et al. A prospective, randomized trial comparing lympho-blastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996; 24: 1366–1370.
    Direct Link:
  • 8
    Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Tagger A, et al. Treatment of chronic hepatitis C with recombinant human interferon-alfa 2a: results of a randomized controlled clinical trial. Hepatology 1994; 19: 1–5.
    Direct Link:
  • 9
    Pozzatto G, Moretti M, Croce LS, Sasso F, Kaneko S, Unoura M, Koba-yashi K, et al. Interferon therapy in chronic hepatitis C virus: evidence of different outcome with respect to different viral strains. J Med Virol 1995; 45: 445–450.
    Direct Link:
  • 10
    Attili AF, Natail L, Onori L, Festuccia V, Natali GF. Treatment of type C chronic active hepatitis with interferon alfa-2a. Treatment duration does not influence biochemical remission but does decrease relapse rate. J Clin Gastroenterol 1994; 19: 214–216.
  • 11
    Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P, Abate ML, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994; 107: 479–485.
  • 12
    Castillo I, Bartolome J, Navas S, Gonzalez S, Herrerro M, Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994; 19: 1342–1346.
    Direct Link:
  • 13
    Douglas DD, Rakela J, Hsiang JL, Hollinger FB, Taswell HW, Czaja AJ, Gross JB, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Dig Dis Sci 1993; 38: 601–607.
  • 14
    Valla D, Babany G, Ouzan D, Trepo C, Bourliere M, Cales P, Payen J-L, et al. Prevention of relapse in patients with chronic non-A, non-B/ C hepatitis who respond to alpha-interferon. A controlled multicenter trial of low-dose maintenance therapy. J Hepatol 1994; 21: 774–778.
  • 15
    Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466.
  • 16
    Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-alfa 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 1273–1280.
  • 17
    Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Kato M, Masuzawa M, et al. Treatment with recombinant interferon-alfa-2 for patients with chronic hepatitis C: predictive factors for biochemical and virological response. Scand J Gastroenterol 1996; 31: 1021–1026.
  • 18
    Chemello L, Cavalletto L, Noventa R, Bonetti P, Casarin C, Bernardi-nello E, Pontisso P, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon alfa. J Viral Hepatitis 1995; 2: 91–96.
    Direct Link:
  • 19
    Diodati G, Bonetti P, Tagger A, Casarin C, Noventa F, Ribero M, Fasola M, et al. Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Dig Dis Sci 1994; 39: 2497–2502.
  • 20
    Bonetti P, Diodati G, Drago C, Casarin C, Scaccabarozzi S, Realdi G, Ruol A, et al. Interferon antibodies in patients with chronic hepatitis C infection treated with recombinant interferon alpha-2a. J Hepatol 1994; 20: 416–420.
  • 21
    Gallorini A, Piebani M, Pontisso P, Chemello L, Masiero M, Mantovani G, Alberti A. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon. Liver 1994; 14: 257–264.
  • 22
    Bonavita MS, Franco A, Paroli M, Santilio I, Benvenuto R, De Petrillo G, Levrero M et al. Normalization of depressed natural killer cell activ-ity after interferon-alfa therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int J Tiss Reac 1993; 15: 11–16.
  • 23
    Kakumu S, Yoshika K, Tanaka K, Higashi Y, Kurokawa S, Hirofuji H, Kusakabe A. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 1993; 41: 65–70.
    Direct Link:
  • 24
    Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, Donada C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. Ann Intern Med 1996; 124: 1058–1060.
  • 25
    Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Spada E, et al. Recombinant interferon-alfa and ursodeoxycholic acid versus interferon-alfa alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995; 90: 263–269.
  • 26
    Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J, Chan K-W, Chu J-S, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307–1312.
  • 27
    Fernandez I, Castellano G, Canga F, Colina F, Garci H, Fuertes A, Casis B, et al. Controlled randomized comparative study of the efficacy of interferon alpha-2b and interferon alpha-2a in the treatment of chronic hepatitis C. Gastroenterologia Y Hepatologia 1995; 18: 22–28.
Get PDF (183K)